-pin(e)
Drugs with a three-ring core.
- Drugs ending in -pin(e): 62
- Approved somewhere: 36
- With a US drug page: 21
What It Means
Stem from WHO's stem book, 2024; description by Arca- Stem
- -pin(e)
- Class
- Drugs with a three-ring core
Drugs That Carry It
Approved and clinical-stage drugs in ChEMBL whose names ending in -pin(e) or one of its sub-stems, matched by spelling; those with a US drug page link to it.| Acts on | |||
|---|---|---|---|
| Benztropine | Approved | CHRM1 | Muscarinic acetylcholine receptor M1 antagonist |
| Choriogonadotropin alfa | Approved | LHCGR | Luteinizing hormone/Choriogonadotropin receptor agonist |
| Corticotropin | Approved | MC2R | Melanocortin receptor 2 agonist |
| Lonapegsomatropin | Approved | GHR | Growth hormone receptor agonist |
| Rifampin | Approved | Bacterial DNA-directed RNA polymerase | Bacterial DNA-directed RNA polymerase inhibitor |
| Somatropin | Approved | GHR | Growth hormone receptor agonist |
| Thyrotropin alfa | Approved | TSHR | Thyroid stimulating hormone receptor agonist |
| Cosyntropin | Phase 3 | MC2R | Melanocortin receptor 2 agonist |
| Gonadotropin, chorionic | Phase 3 | LHCGR | Luteinizing hormone/Choriogonadotropin receptor agonist |
| Urofollitropin | Phase 3 | FSHR | Follicle stimulating hormone receptor agonist |
| Atropine | Approved | CHRM3, CHRM1, CHRM2 | Muscarinic acetylcholine receptor M3 antagonist |
| Corifollitropin alfa | Approved | FSHR | Follicle stimulating hormone receptor agonist |
| Dibenzepin | Approved | HRH1, SLC6A2 | Histamine H1 receptor antagonist |
| Dothiepin | Approved | SLC6A2, SLC6A4 | Norepinephrine transporter inhibitor |
| Follitropin | Approved | FSHR | Follicle stimulating hormone receptor agonist |
| Follitropin alfa | Approved | FSHR | Follicle stimulating hormone receptor agonist |
| Follitropin beta | Approved | FSHR | Follicle stimulating hormone receptor agonist |
| Follitropin delta | Approved | FSHR | Follicle stimulating hormone receptor agonist |
| Lutropin alfa | Approved | LHCGR | Luteinizing hormone/Choriogonadotropin receptor agonist |
| Methylatropine | Approved | — | — |
| Methylhomatropine | Approved | — | Unknown |
| Pilocarpine | Approved | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 agonist |
| Albusomatropin | Phase 3 | — | — |
| Emoxypine | Phase 3 | — | — |
| Genipin | Phase 3 | — | — |
| Thyrotropin | Phase 3 | TSHR | Thyroid stimulating hormone receptor agonist |
| Bamipine | Phase 2 | — | — |
| Deptropine | Phase 2 | — | — |
| Droxypropine | Phase 2 | — | — |
| Ethybenztropine | Phase 2 | — | — |
| Redalsomatropin alfa | Phase 2 | — | — |
| Somatropin pegol | Phase 2 | — | — |
| Zosurabalpin | Phase 2 | — | — |
| Cordycepin | Phase 1 | — | — |
| Terpin | Phase 1 | — | — |
| Anisotropine | — | CHRM3, CHRM1 | Muscarinic acetylcholine receptor M3 antagonist |
| Corticotropin zinc hydroxide | — | MC2R | Melanocortin receptor 2 agonist |
| Indalpine | — | SLC6A4 | Serotonin transporter inhibitor |
| Amoxapine | Approved | SLC6A4, SLC6A2, Dopamine receptor | Serotonin transporter inhibitor |
| Clozapine | Approved | HTR2A, DRD2 | Serotonin 2a (5-HT2a) receptor antagonist |
| Mirtazapine | Approved | HTR2A, HTR2C, Adrenergic receptor alpha-2 | Serotonin 2a (5-HT2a) receptor antagonist |
| Nevirapine | Approved | POL | Human immunodeficiency virus type 1 reverse transcriptase inhibitor |
| Olanzapine | Approved | HTR2A, HTR2C, D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor antagonist |
| Quetiapine | Approved | HTR2A, HTR2C, DRD2 | Serotonin 2a (5-HT2a) receptor antagonist |
| Asenapine | Approved | DRD2, HTR2A | Dopamine D2 receptor antagonist |
| Clothiapine | Approved | Serotonin 2 (5-HT2) receptor, DRD4, Serotonin 3 (5-HT3) receptor | Serotonin 2 (5-HT2) receptor antagonist |
| Loxapine | Approved | HTR2A, HTR2C, D2-like dopamine receptor | Serotonin 2a (5-HT2a) receptor antagonist |
| Noscapine | Approved | — | — |
| Esmirtazapine | Phase 3 | HRH1, HTR2A, HTR2C, Adrenergic receptor alpha-2 | Histamine H1 receptor antagonist |
| Zicronapine | Phase 3 | — | — |
| Triapine | Phase 2 | RRM1, RRM2B | Ribonucleotide reductase inhibitor |
| Doxepin | Approved | SLC6A2, HRH1 | Norepinephrine transporter inhibitor |
| Zotepine | Approved | — | — |
| Tropatepine | Phase 2 | — | — |
| Carbamazepine | Approved | Sodium channel alpha subunit | Sodium channel alpha subunit blocker |
| Eslicarbazepine | Approved | Sodium channel alpha subunit | Sodium channel alpha subunit blocker |
| Eslicarbazepine acetate | Approved | Sodium channel alpha subunit | Sodium channel alpha subunit blocker |
| Oxcarbazepine | Approved | Sodium channel alpha subunit | Sodium channel alpha subunit blocker |
| Pirenzepine | Approved | CHRM1 | Muscarinic acetylcholine receptor M1 antagonist |
| Benzodiazepine | Phase 3 | — | — |
| Licarbazepine | Phase 3 | — | — |
| Telenzepine | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO